KRT7 Monoclonal Antibody

說明書

中文名稱：

KRT7鼠單克隆抗體
貨號：

CSB-MA634481
規格：

￥1320
圖片：
IHC image of CSB-MA634481 diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-mouse IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

【KRT7單克隆抗體】CUSABIO貨號：CSB-MA634481是針對人源角蛋白7（KRT7）研發的高特異性科研試劑。KRT7屬于II型細胞角蛋白家族，在上皮細胞分化過程中發揮結構支撐作用，其異常表達與多種腺癌及轉移性腫瘤密切相關，是鑒別腫瘤組織起源的重要分子標志物。本產品采用雜交瘤技術制備，經ELISA與免疫組化（IHC）雙重平臺驗證，可精準識別天然構象的KRT7蛋白，適用于福爾馬林固定石蠟包埋（FFPE）組織切片及細胞樣本的定位分析。在腫瘤微環境研究、上皮間質轉化機制探索及轉移性病灶鑒別等科研場景中，該抗體能有效支持KRT7蛋白表達水平的定量檢測與空間分布研究，為癌癥生物標志物篩選、病理分型輔助鑒定提供可靠工具。產品嚴格質控確保批次穩定性，配套實驗方案助力研究者快速開展消化道腫瘤、乳腺癌等上皮源性疾病的分子病理學研究。
產品名稱：

Mouse anti-Homo sapiens (Human) KRT7 Monoclonal antibody
Uniprot No.：

P08729
基因名：

KRT7
別名：

CK 7 antibody; CK-7 antibody; CK7 antibody; Cytokeratin 7 antibody; Cytokeratin-7 antibody; D15Wsu77e antibody; K2C7 antibody; K2C7_HUMAN antibody; K7 antibody; Keratin 7 antibody; Keratin 7; type II antibody; Keratin type II cytoskeletal 7 antibody; Keratin; 55K type II cytoskeletal antibody; Keratin; simple epithelial antibody; Keratin; simple epithelial type I; K7 antibody; Keratin; type II cytoskeletal 7 antibody; Keratin-7 antibody; Krt2-7 antibody; KRT7 antibody; MGC11625 antibody; MGC129731 antibody; MGC3625 antibody; Sarcolectin antibody; SCL antibody; Type II mesothelial keratin K7 antibody; Type-II keratin Kb7 antibody
宿主：

Mouse
反應種屬：

Human
免疫原：

Synthesized peptide derived from human Cytokeratin 7
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

IgG1, Kappa
純化方式：

The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
克隆號：

24D7
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Blocks interferon-dependent interphase and stimulates DNA synthesis in cells. Involved in the translational regulation of the human papillomavirus type 16 E7 mRNA (HPV16 E7).
基因功能參考文獻：
1. Data indicate that de novo expression of KRT7 and KRT19 resulting in altered plasticity and stem cell characteristics of epithelial cells might be a crucial factor in increasing the risk of tumor development in end-stage kidneys. PMID: 30194170
2. High expression of CK-7 is associated with intrahepatic cholangiocarcinoma. PMID: 29513894
3. Positive expression of CK7 associated with pathological features of lymph node metastasis and T stage may be independent clinical parameters for poor prognosis of patients with lung cancer. PMID: 28827446
4. Research show that circulating CK7 mRNA positive cells were found in patients with bladder urothelial cancer of varying stages, and the detection rates increased with stage predicting worse clinical scenario. PMID: 28024950
5. CK7/ HPV-L1 expression, and the presence of koilocytosis can be used for prognostication in patients with cervical low-grade squamous intraepithelial lesions. PMID: 28554573
6. KRT7-AS formed an RNA-RNA hybrid with KRT7 and controlled KRT7 expression at both the mRNA and the post-transcriptional levels. forced overexpression of the KRT7-overlapping region (OL) of KRT7-AS (but not its non-KRT7-OL portions) increased keratin 7 protein levels in cells. Finally, forced overexpression of full-length KRT7-AS or OL KRT7-AS (but not its non-KRT7-OL regions) promoted GC cell proliferation PMID: 26876208
7. These data support the theory that CK7 staining may inform risk stratification for low-grade squamous intraepithelial cervical lesions (CIN1). PMID: 27680604
8. the status of K7 expression in metastatic lymph nodes from colorectal carcinoma is a poor prognostic factor PMID: 28155971
9. Mismatch repair (MMR) defects influence the expression of clinically important biomarkers for endometrioid-type endometrial carcinoma as decreased cytokeratin 7 expression is more commonly associated with MMR deficiency. PMID: 25851713
10. Ischemic parenchymal changes are characterized by hepatocyte K7 immunoexpression PMID: 26887669
11. Survival analysis showed that the non-small cell lung carcinoma patients with enhanced expression of CK7, ELF3, EGFR, and EphB4 mRNA in peripheral blood leukocytes had poorer disease-free survival and overall survival than those without. PMID: 27827952
12. Keratin 34betaE12/K7 expression is a prognostic parameter in resected early stage NSCLC that allows identification of high-risk NSCLC patients with poor cancer-specific and overall survival. PMID: 26057535
13. K7 expression was also detected in 72 of 75 triple-negative carcinoma cases PMID: 26670478
14. CK7, TTF-1 and napsin A are predominantly expressed in primary lung adenocarcinoma patients, with CDX-2 being inconsistently expressed. PMID: 26469326
15. CK7 staining was notably heterogeneous, with 14.5% of all cases demonstrating PMID: 22748158
16. Data show that cytokeratin-7 (KRT7) mRNA expression serves as a sensitive approach for the molecular detection of KRT7-positive circulating tumour cells (CTCs)-resembling A549 cells in peripheral whole blood. PMID: 26306784
17. Cytokeratin 7 positivity in cervical low-grade squamous intraepithelial lesion is a marker for risk of progression to a high-grade lesion. PMID: 26551618
18. Immunostaining for CK7 and epithelial membrane antigen can be used to differentiate interlobular bile ducts from ductular proliferation in patients with cholestasis. PMID: 26366614
19. Epithelial-mesenchymal transition-related proteins CK-7 and alpha-SMA colocalized to the intrahepatic biliary epithelial cells in patients with biliary atresia. PMID: 25406900
20. The immunofluorescent staining pattern of Wnt1 and CK7 as well as Wnt1 and CK13 was consistent with IHC results. Thus, in pleomorphic adenoma, Wnt is involved in tumor cell differentiation of peripheral columnar cells forming solid nests PMID: 25076852
21. The present study confirmed that CK14, but not CK20 or CK7, is expressed in urothelial carcinoma with squamous differentiation and squamous cell carcinoma of the urinary bladder. PMID: 25643514
22. Our results suggested that a combination of CK7 and TP53 immunohistochemistry may be helpful in diagnosing inflammatory bowel disease-associated dysplasia in difficult cases. PMID: 23887291
23. BRAF-mutated microsatellite stable colorectal carcinoma often displays reduced CDX2 and increased CK7 expression PMID: 24908142
24. Loss of cytokeratin 7 is associated with reduced response to concommitant radiochemotherapy for locally advanced cervical cancer. PMID: 24403459
25. CK7 and Cam 5.2 expression may occur in SCC. A panel including Ber-Ep4 is advisable for immunohistochemical differentiation of EPD from SCC. PMID: 23590728
26. Of the cases of clear cell renal carcinoma there was immunoreactivity for alpha-methylacyl-CoA racemase and strong diffuse immuno-positivity for cytokeratin. PMID: 23434146
27. CK7 + centrilobular hepatocytes occur relatively frequently in non-neoplastic liver disease, associated with centrilobular scarring and CK7-positive periportal hepatocytes, and appear to be a non-specific phenomenon of underlying disease. PMID: 22716237
28. Heterogeneity of cytokeratin 7 expression in pagetoid Bowen's disease. PMID: 22390404
29. Pouch/peripouch and UC-associated adenocarcinoma had a comparable positive rate for CK7, CK20, and CDX2 by immunohistochemistry. PMID: 22895272
30. High Cytokeratin-7 is associated with esophageal squamous cell carcinoma. PMID: 22203179
31. Both the CK7-/CK20+ phenotype and expression of the antibody CDX2 are highly specific and sensitive markers of colorectal origin. PMID: 22268990
32. This is the first reported study of the relationship between CK20/CK7 immunophenotype, BRAF mutations and microsatellite status in colorectal carcinomas PMID: 22361037
33. None of the Wilms' tumors-associated lesions were positive for KRT7, but 69-80% of lesions associated with pRCpapillary renal cell tumors and mucinous tubular and spindle cell carcinomas were positive for KRT7. PMID: 22382985
34. The expressions of CK7 and CK20 in nasal polyps were analyzed. PMID: 22119824
35. Aberrant expression of K7 in budding cancer cells represents a modification of the epithelial phenotype ('epithelial-epithelial transition': EET) which may be linked to gains in motility and invasive potential. PMID: 21884201
36. CK-7 expression grades correlated positively with histological stages of primary biliary cirrhosis (r=0.639, P<0.000) and negatively with granulomas (r=-0.432, P<0.0001; OR=0.173, P=0.0011). PMID: 21681009
37. Our results reveal that menopause influences the adipose tissue expression of many genes, especially of neurexin 3, metallothionein 1E, and keratyn 7, which are associated with the alteration of several key biological processes. PMID: 21358552
38. Our results along with the data from the literature indicate that CK7/CK20 expression may be of clinical significance. PMID: 21574103
39. Case Report: Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma, negative for cytokeratin 7. PMID: 20727680
40. A considerable number of colorectal carcinomas showed immunoreactivity to CK7. PMID: 21282015
41. Hepatocyte CK7 expression is frequently noted in chronic allograft rejection, and it would appear to reflect ductopenia. PMID: 21228364
42. Immunohistochemistry for cytokeratins 7 and 19, which mark biliary epithelium, is helpful in the diagnosis of biliary diseases. PMID: 20538416
43. Endometrial adenocarcinomas show micro-anatomical variations in Ki67 expression and this is often inversely correlated with CK7 immunoreactivity. PMID: 20557372
44. Case Report: CK7+/CK20- Merkel cell carcinoma presenting as inguinal subcutaneous nodules with subsequent epidermotropic metastasis. PMID: 20574624
45. the expression of Cytokeratins 7, 8, 18, and 19 may serve as differential diagnostic markers for pulmonary large cell neuroendocrine carcinoma and small cell lung carcinoma PMID: 20398190
46. CK7 is a possible marker for colorectal carcinogenesis. PMID: 17715023
47. FOXA1 induces not only KRT7 but also LOXL2 in a subset of poor prognostic esophageal squamous cell carcinomas with metastatic lymph nodes PMID: 20043065
48. Toker cells and mammmary Paget cells share immunoreactivity to CK7. PMID: 20001343
49. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction PMID: 11962749
50. HPV16 E7 mRNA-cytokeratin 7 binding in squamous cervical cancer SiHa cells occurs through the 6-mer peptide SEQIKA present in human cytokeratin 7 protein PMID: 12072504
顯示更多

收起更多
亞細胞定位：

Cytoplasm.
蛋白家族：

Intermediate filament family
組織特異性：

Expressed in cultured epidermal, bronchial and mesothelial cells but absent in colon, ectocervix and liver. Observed throughout the glandular cells in the junction between stomach and esophagus but is absent in the esophagus.
數據庫鏈接：

HGNC: 6445

OMIM: 148059

KEGG: hsa:3855

STRING: 9606.ENSP00000329243

UniGene: Hs.411501

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
VDAC1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human, Mouse, Rat
VCP Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, IP

Species Reactivity: Human, Rat